相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease
Meygal Kahana et al.
MOLECULAR PSYCHIATRY (2021)
Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson's disease therapy
Yung-Chih Kuo et al.
ACTA BIOMATERIALIA (2021)
Safe Nanoparticles: Are We There Yet?
Wided Najahi-Missaoui et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics
Amna Akhtar et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Nanomaterials: Synthesis and Applications in Theranostics
Gokul Paramasivam et al.
NANOMATERIALS (2021)
Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
Sara Silva et al.
PHARMACEUTICS (2021)
Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson's Disease
Victoria Monge-Fuentes et al.
SCIENTIFIC REPORTS (2021)
Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation
Zhaogang Yang et al.
NATURE BIOMEDICAL ENGINEERING (2020)
Microbial astaxanthin biosynthesis: recent achievements, challenges, and commercialization outlook
Congqiang Zhang et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2020)
Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson's Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation
Narendar Dudhipala et al.
PHARMACEUTICS (2020)
Investigation on corrosion inhibition and adsorption mechanism of triazine-thiourea derivatives at mild steel/HCl solution interface: Electrochemical, XPS, DFT and Monte Carlo simulation approach
Priya Kumari Paul et al.
JOURNAL OF ELECTROANALYTICAL CHEMISTRY (2020)
Sustainable technologies for liposome preparation
Maja Leitgeb et al.
JOURNAL OF SUPERCRITICAL FLUIDS (2020)
A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems
Yongtao Duan et al.
RSC ADVANCES (2020)
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Emerging Lipid Based Drug Delivery Systems
Rupesh K. Shirodkar et al.
PHARMACEUTICAL CHEMISTRY JOURNAL (2019)
Dopamine: Functions, Signaling, and Association with Neurological Diseases
Marianne O. Klein et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2019)
Comparison of Kinetics, Toxicity, Oligomer Formation, and Membrane Binding Capacity of α-Synuclein Familial Mutations at the A53 Site, Including the Newly Discovered A53V Mutation
Ganesh M. Mohite et al.
BIOCHEMISTRY (2018)
Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance
Manon Auffret et al.
CLINICAL DRUG INVESTIGATION (2018)
Nanoparticles in Cancer Treatment: Opportunities and Obstacles
Rajendra Awasthi et al.
CURRENT DRUG TARGETS (2018)
A brain targeting functionalized liposomes of the dopamine derivative &ITN&IT-3, 4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease
Mengke Qu et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review
Sergio Davinelli et al.
NUTRIENTS (2018)
Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease
Mengke Qu et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Astaxanthin-Loaded Nanostructured Lipid Carriers for Preservation of Antioxidant Activity
Violeta Rodriguez-Ruiz et al.
MOLECULES (2018)
Magnetic Resveratrol Liposomes as a New Theranostic Platform for Magnetic Resonance Imaging Guided Parkinson's Disease Targeting Therapy
Meili Wang et al.
ACS SUSTAINABLE CHEMISTRY & ENGINEERING (2018)
Contrast-enhanced Digital Mammography: A Single-Institution Experience of the First 208 Cases
Tiffany C. Lewis et al.
BREAST JOURNAL (2017)
Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases
Christos Tapeinos et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson's Disease
Paromita Kundu et al.
ACS CHEMICAL NEUROSCIENCE (2016)
Use of PEGylated Immunoliposomes to Deliver Dopamine Across the Blood-Brain Barrier in a Rat Model of Parkinson's Disease
Young-Sook Kang et al.
CNS NEUROSCIENCE & THERAPEUTICS (2016)
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD)
Caroline H. Williams-Gray et al.
MOVEMENT DISORDERS (2016)
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease
Roberto Di Maio et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Nose to brain delivery of astaxanthin-loaded solid lipid nanoparticles: fabrication, radio labeling, optimization and biological studies
Prakash Chandra Bhatt et al.
RSC ADVANCES (2016)
Nanostructured lipid carriers and their current application in targeted drug delivery
Piyush Jaiswal et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2016)
Trans-Blood Brain Barrier Delivery of Dopamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Rats
Richa Pahuja et al.
ACS NANO (2015)
Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey
N. Bernard et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2015)
Liposomes as nanomedical devices
Giuseppina Bozzuto et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease
Alicia M. Pickrell et al.
NEURON (2015)
Mitochondrial Dysfunction in Parkinson's Disease
Hyo Eun Moon et al.
EXPERIMENTAL NEUROBIOLOGY (2015)
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Yuchen Fan et al.
VACCINES (2015)
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application
Neda Naseri et al.
ADVANCED PHARMACEUTICAL BULLETIN (2015)
The Newly Discovered Parkinson's Disease Associated Finnish Mutation (A53E) Attenuates α-Synuclein Aggregation and Membrane Binding
Dhiman Ghosh et al.
BIOCHEMISTRY (2014)
Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling
Darren Michael Moss et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Surface engineering of silica nanoparticles for oral insulin delivery: Characterization and cell toxicity studies
Tatiana Andreani et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2014)
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells
Mohamed-Bilal Fares et al.
HUMAN MOLECULAR GENETICS (2014)
Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route
Yasmine M. Gabal et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-dependent, Ca2+-induced Mitochondrial Dysfunction
Eric S. Luth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
A G4•K+ Hydrogel Stabilized by an Anion
Gretchen Marie Peters et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats
Ying-Zheng Zhao et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
A critical review of lipid-based nanoparticles for taxane delivery
Lan Feng et al.
CANCER LETTERS (2013)
Cell-Cell Communication between Malaria-Infected Red Blood Cells via Exosome-like Vesicles
Neta Regev-Rudzki et al.
CELL (2013)
Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach
Chandrakantsing V. Pardeshi et al.
DRUG DELIVERY (2013)
Biocompatibility of engineered nanoparticles for drug delivery
Sheva Naahidi et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
Maria Xilouri et al.
MOLECULAR NEUROBIOLOGY (2013)
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Michael L. Etheridge et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Properties of native brain α-synuclein
Jacqueline Burre et al.
NATURE (2013)
Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia
Paul Edison et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Effects of Particle Size and Surface Modification on Cellular Uptake and Biodistribution of Polymeric Nanoparticles for Drug Delivery
Sneha A. Kulkarni et al.
PHARMACEUTICAL RESEARCH (2013)
Liposome: classification, preparation, and applications
Abolfazl Akbarzadeh et al.
NANOSCALE RESEARCH LETTERS (2013)
Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes
Xin Liu et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Solid lipid based nanocarriers: An overview
Chandrakantsing Pardeshi et al.
ACTA PHARMACEUTICA (2012)
Toxicology of nanoparticles
Andreas Elsaesser et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Target delivery of a gene into the brain using the RVG29-oligoarginine peptide
Cheng Gong et al.
BIOMATERIALS (2012)
The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model
Fahima Dilnawaz et al.
BIOMATERIALS (2012)
Lyotropic liquid crystal engineering-ordered nanostructured small molecule amphiphile self-assembly materials by design
Celesta Fong et al.
CHEMICAL SOCIETY REVIEWS (2012)
Transport of drugs across the blood-brain barrier by nanoparticles
Stefanie Wohlfart et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson's disease in the MPTP-induced mice model
Yu Xiang et al.
JOURNAL OF DRUG TARGETING (2012)
Nanostructured Lipid Carriers: A potential drug carrier for cancer chemotherapy
Subramanian Selvamuthukumar et al.
LIPIDS IN HEALTH AND DISEASE (2012)
Rotenone, Paraquat, and Parkinson's Disease
Caroline M. Tanner et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2011)
Oral Apomorphine Delivery from Solid Lipid Nanoparticles with Different Monostearate Emulsifiers: Pharmacokinetic and Behavioral Evaluations
Ming-Jun Tsai et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in Parkinsonian rats
Yanchun Wang et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Lydia Alvarez-Erviti et al.
NATURE BIOTECHNOLOGY (2011)
Use of ibuprofen and risk of Parkinson disease
Xiang Gao et al.
NEUROLOGY (2011)
Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death
Laura A. Volpicelli-Daley et al.
NEURON (2011)
Idebenone and Resveratrol Extend Lifespan and Improve Motor Function of HtrA2 Knockout Mice
Ellen Gerhardt et al.
PLOS ONE (2011)
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters
Svetlana Gelperina et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2010)
Parkin Directly Modulates 26S Proteasome Activity
Ji Won Um et al.
JOURNAL OF NEUROSCIENCE (2010)
Structure and function of the blood-brain barrier
N. Joan Abbott et al.
NEUROBIOLOGY OF DISEASE (2010)
Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating Off Episodes in Advanced Parkinson Disease
Peter A. LeWitt et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Recent Advances in Medicinal Chemistry and Pharmaceutical Technology-Strategies for Drug Delivery to the Brain
Nunzio Denora et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models
Damla Pinar Karpinar et al.
EMBO JOURNAL (2009)
Lipid nanoparticles for parenteral delivery of actives
Medha D. Joshi et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
Nanoparticle-based targeted drug delivery
Rajesh Singh et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2009)
Differential receptor-mediated drug targeting to the diseased brain
J. Rip et al.
EXPERT OPINION ON DRUG DELIVERY (2009)
Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology
Karin M. Danzer et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
K. Ray Chaudhuri et al.
LANCET NEUROLOGY (2009)
L-dopa therapy for Parkinson's disease: Past, present, and future
Toshiharu Nagatsu et al.
PARKINSONISM & RELATED DISORDERS (2009)
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease
Tianhong Pan et al.
BRAIN (2008)
Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain
Latha Devi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Epidemiology of Parkinson's disease
Guido Alves et al.
JOURNAL OF NEUROLOGY (2008)
The blood-brain barrier in health and chronic neurodegenerative disorders
Berislav V. Zlokovic
NEURON (2008)
Solid lipid nanoparticles as delivery systems for bromocriptine
Elisabetta Esposito et al.
PHARMACEUTICAL RESEARCH (2008)
L-DOPA is an endogenous ligand for OA1
Vanessa M. Lopez et al.
PLOS BIOLOGY (2008)
Transvascular delivery of small interfering RNA to the central nervous system
Priti Kumar et al.
NATURE (2007)
Dopamine and adult neurogenesis
Andreas Borta et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+-induced toxicity in PC12 cells
Keith Chiasson et al.
NEUROTOXICITY RESEARCH (2006)
Apomorphine in dopaminergic therapy
J. Anand Subramony
MOLECULAR PHARMACEUTICS (2006)
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
A Gerhard et al.
NEUROBIOLOGY OF DISEASE (2006)
Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration
K Manjunath et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Neurovascular mechanisms of Alzheimer's neurodegeneration
BV Zlokovic
TRENDS IN NEUROSCIENCES (2005)
Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain
J Kreuter
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2004)
Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway
HJ Lee et al.
JOURNAL OF NEUROSCIENCE (2004)
PINK1 mutations are associated with sporadic early-onset parkinsonism
EM Valente et al.
ANNALS OF NEUROLOGY (2004)
Neuronal nicotinic receptors: from structure to pathology
C Gotti et al.
PROGRESS IN NEUROBIOLOGY (2004)
Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene -: cytotoxicity testing and mouse serum adsorption
C Olbrich et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Solid lipid nanoparticles for parenteral drug delivery
SA Wissing et al.
ADVANCED DRUG DELIVERY REVIEWS (2004)
Altered proteasomal function in sporadic Parkinson's disease
KS McNaught et al.
EXPERIMENTAL NEUROLOGY (2003)
Rare genetic mutations shed light on the pathogenesis of Parkinson disease
TM Dawson et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain
S Ohtsuki et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease
KSP McNaught et al.
NEUROSCIENCE LETTERS (2002)
Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) -: effect of surfactants, storage time and crystallinity
C Olbrich et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2002)
α-Synuclein is phosphorylated in synucleinopathy lesions
H Fujiwara et al.
NATURE CELL BIOLOGY (2002)
Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein
EJ Jo et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
DC Wu et al.
JOURNAL OF NEUROSCIENCE (2002)
Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability
KA Witt et al.
PEPTIDES (2001)
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
Y He et al.
BRAIN RESEARCH (2001)
Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression
JD Huber et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2001)
Proteasomal function is impaired in substantia nigra in Parkinson's disease
KSP McNaught et al.
NEUROSCIENCE LETTERS (2001)
Solid lipid nanoparticles (SLN) for controlled drug delivery -: a review of the state of the art
RH Müller et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2000)
分享论文
